Latest Conference Articles

Discussing research related to TAVR with a cardiac surgeon from Brigham and Women's Hospital.

Discussing takeaways from the late-breaking abstracts related to TAVR presented at ACC.20/WCC with a cardiac surgeon from Brigham and Women's Hospital.

The latest piece coming to us through Notes from Rounds examines how the timing of hormone replacement therapy can impact potential for adverse outcomes.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

A discussion on how the COVID-19 outbreak might impact burnout among cardiologists and other medical professionals.

Discussing a study examining rates of burnouts in cardiology with lead investigator Laxmi Mehta, MD, director of preventative cardiology and women’s cardiovascular health at Ohio State University.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

Results of a TWILIGHT subanalysis suggest ticagrelor monotherapy might cause less bleeding without increasing events in patients with requiring complex PCI.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Results of the CARAVAGGIO trial found oral apixaban was noninferior to subcutaneous dalteparin for preventing cancer-associated VTE without increasing a patient’s risk for major bleeding.

Results of the SPYRAL-HTN OFF MED indicate renal denervation could prove useful for lowering SBP in patients with untreated hypertension.

Marc Bonaca, MD, discusses the results of a subgroup analysis examining the impact of concomitant clopidogrel use in VOYAGER-PAD study.

New PRONOMOS data shows patients receiving lower limb surgery benefit significant from the oral anticoagulant—without increased risk of bleeding.

Results of POPular TAVI indicate concomitant clopidogrel with oral anticoagulants increases risk of bleeding in patients requiring long-term anticoagulation after TAVI.

New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.

A new ACC 2020 study shows the modifiable levels of CVD risk are distinguishable to long-term event possibility.

A heart failure and transplant cardiologist assesses the new study findings.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.